New tradition in biotechnology

Follow us

Biotech Lab 4.0

Vaccine development by design

A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.

AchilleS Vaccines Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.

Our Technology

AchilleS Vaccines exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.

Next Generation Reverse Vaccinology (NGRV)

NGRV is an evolution of the classic Reverse Vaccinology method. NGRV exploits advanced laboratory and digital technologies for precise and rapid identification of more effective vaccine targets.

Homologous and heterologous antigen expression in bacterial vaccine platforms, high-throughput immunology, single cell and omics capabilities, analytic vaccinology and immortalized memory B-cells are among the tools and technologies which enable AchilleS Vaccines to perform Next Generation Reverse Vaccinology.

modified Outer Membrane Vesicles (mOMV)

A versatile technology platform that exploits bacteria for the production of self adjuvanting vesicles able to deliver antigenic molecules.

This technology has great advantages for product development, including large-scale, cost-effective productionmOMV have demonstrated good tolerability and high immunogenicity in humans.


Covid-19 is a respiratory Coronavirus that has recently escalated worldwide to pandemic levels, becoming a Public Health Emergency of International Concern.

No licensed vaccines, immune therapeutics or effective drugs are currently available. The MAbCo19 project aims to rapidly deliver a human neutralizing monoclonal antibody as a prophylactic and therapeutic tool against Covid-19.


Malaria still remains a grave infectious disease that impacts on the life and prosperity of the world population.

In recent times there have been over 200 million annual cases of malaria worldwide, leading to over 400.000 deaths. Children aged under 5 years are the most vulnerable group. Malaria can also be a predisposing co-morbidity for a number of other infections including fatal bacterial septicamias.

AchilleS Vaccines aims to move away from traditional approaches and use multidisciplinary, combinatorial, innovative science towards the development of a new malaria vaccine.

Solutions to fight AMR pathogens

Bacterial infections remain a serious threat for humanity. The increasing impact of antimicrobial resistance could create a global crisis with 10 million death per year in 2050.

We will use our R&D platforms to develop vaccines and immuno-therapeutics against Gram-negative bacteria that have a high level of antimicrobial resistance worldwide.

They Talk About Us

La sfida di Riccardo Baccheschi, presidente di AchilleS Vaccines: "Apriremo laboratori 4.0 negli spazi di Tls, finanziati dal Governo”
QN La Nazione
09 Giugno 2020
Achilles Vaccines, impegnata nello sviluppo di vaccini e biofarmaci ad alto contenuto tecnologico, si conferma protagonista internazionale nell’area life sciences.
Agosto 2020
Colpisce, anzitutto, che Achilles Vaccines è la prima società in ambito vaccinale nel nostro Paese ad essersi dotata di un progetto di laboratorio 4.0
la Repubblica
22 Giugno 2020
L’investimento che AchilleS Vaccines si è aggiudicata rappresenta il più cospicuo seed financing mai assegnato a una società italiana in ambito biotech.
Milano Finanza
12 Giugno 2020

Latest News

Scientific Collaborations